{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088482","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.200278+00:00","generated_at":"2026-05-19T01:30:53.959705+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"4D Molecular Therapeutics annual meeting results: all four proposals approved","bullets":["Stockholders elected Jacob Chacko, Susannah Gray, and Charles Theuer as Class II directors.","Ratified PricewaterhouseCoopers as independent auditor for FY2025.","Say-on-pay proposal approved (31.8M for, 394k against, 35k abstain, 6.2M broker non-votes).","Advisory vote on future say-on-pay frequency: one year chosen; company will hold annual votes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088482","json":"https://secwatch.observer/filing/0000950170-25-088482.json","markdown":"https://secwatch.observer/filing/0000950170-25-088482.md","text":"https://secwatch.observer/filing/0000950170-25-088482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088482/0000950170-25-088482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088482/fdmt-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:30:53.959705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}